First Time Loading...

Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392

Watchlist Manager
Beijing Wantai Biological Pharmacy Enterprise Co Ltd Logo
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Watchlist
Price: 68.65 CNY -2.25% Market Closed
Updated: May 8, 2024

Beijing Wantai Biological Pharmacy Enterprise Co Ltd
Cash from Financing Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Beijing Wantai Biological Pharmacy Enterprise Co Ltd
Cash from Financing Activities Peer Comparison

Comparables:
6160
1801
B
600161
300122
300896

Competitive Cash from Financing Activities Analysis
Latest Figures & CAGR of Competitors

Company Cash from Financing Activities CAGR 3Y CAGR 5Y CAGR 10Y
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Cash from Financing Activities
-¥893.3m
CAGR 3-Years
N/A
CAGR 5-Years
-98%
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Cash from Financing Activities
-¥448.1m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Innovent Biologics Inc
HKEX:1801
Cash from Financing Activities
¥2.9B
CAGR 3-Years
-16%
CAGR 5-Years
-8%
CAGR 10-Years
N/A
B
Beijing Tiantan Biological Products Corp Ltd
SSE:600161
Cash from Financing Activities
-¥508.1m
CAGR 3-Years
N/A
CAGR 5-Years
13%
CAGR 10-Years
N/A
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Cash from Financing Activities
-¥2.4B
CAGR 3-Years
-5%
CAGR 5-Years
N/A
CAGR 10-Years
-39%
Imeik Technology Development Co Ltd
SZSE:300896
Cash from Financing Activities
-¥374.2m
CAGR 3-Years
-104%
CAGR 5-Years
-98%
CAGR 10-Years
N/A

See Also

What is Beijing Wantai Biological Pharmacy Enterprise Co Ltd's Cash from Financing Activities?
Cash from Financing Activities
-893.3m CNY

Based on the financial report for Dec 31, 2023, Beijing Wantai Biological Pharmacy Enterprise Co Ltd's Cash from Financing Activities amounts to -893.3m CNY.

What is Beijing Wantai Biological Pharmacy Enterprise Co Ltd's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 5Y
-98%